Table 1.
Current immunotherapy trials for patients with relapsed/refractory ALL.
| Title | Registration Number | Eligible Ages | Sponsor |
|---|---|---|---|
| Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ZUMA-4) | NCT026525480 | 2–21 years | KITE/Gilead, Los Angeles, CA, USA |
| Transposon-Manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients with r/r ALL Post HSCT (CARCIK) | NCT03389035 | 1–75 year | Fondazione Matilde Tettamanti Menotti De Marchi Onlus, Monza MI, Italy |
| Evaluation of CD19-specific CAR Engineered Autologous T-cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | NCT03573700 | ≤21 years | St. Jude Children’s Research Hospital, Memphis, TN, USA |
| CD19 T-CAR for Treatment of Children and Young Adults with r/r B-ALL | NCT03467256 | 3 months to 25 years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russia |
| Study of UCART19 in Pediatric Patients with Relapsed/Refractory B Acute Lymphoblastic Leukemia (PALL) | NCT02808442 | 6 months to 17 years | Insitut de Recherches Internationales Servier, Paris, France |
| CAR-20/19-T cells in Pediatric Patients with Relapsed/Refractory B cell ALL (CAR-20/19-T) | NCT04049383 | 1–39.99 years | Medical College of Wisconsin, Milwaukee, WI, USA |
| Study of efficacy and safety of tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA) | NCT03876769 | 1–25 years | Novartis, Basel, Switzerland |
| Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL | NCT03792622 | 1–29 years | University of Pennsylvania, Philadephia, PA, USA |
| T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults with B-Cell Malignancies | NCT02772198 | 1–50 years | Sheba Medical Center, Ramat Gan, Israel |
| Anti-CD19 CAR T cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ALL and NHL | NCT03373071 | 6 months-25 years | Bambino Gesu Hospital and Research Institute, Rome, Italy |
| Anti-CD19, Dual Co-Stimulatory (4–1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients with relapsed/refractory aggressive lymphoma or acute lymphoblastic leukemia (ALL) (ACIT001/EXC002) | NCT03938987 | 2–70 years | University of Alberta, Edmonton, Alberta, Canada |
| CD22-Redirected Autologous T cells for ALL | NCT02650414 | 1–24 years | University of Pennsylvania, Philadephia, PA, USA |
| Administration of Autologous CAR-T CD19 Antigen with inducible Safety Switch in Patients with Relapsed/Refractory ALL | NCT03016377 | 3–70 years | UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA |
| MB-CART19.1 in Patients with R/R ALL | NCT03321123 | 2 months - 18 years | Shanghai Children’s Medical Center, Shanghai, China |
| Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 In Patients with Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated with Cell Therapy | NCT02374333 | 1–24 years | University of Pennsylvania, Philadephia, PA, USA |
| Patient-Individualized Peptide Vaccination Based On Tumor-specific Mutations in Children and Young Adults with Primary/Relapsed ALL | NCT035559413 | 1–30 years | University Children’s Hospital Tuebingen, Tuebingen, Germany |
| MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) | NCT03853616 | ≥1 year | Miltenyi Biotec GmbH, Bergisch Gladbach, Germany |
| Treatment of Patients with Relapsed or Refractory CD19+ Lymphoid Disease with T cells Expressing a Third- Generation CAR | NCT03676504 | ≥3 years | University Hospital Heidelberg, Heidelberg, Germany |
| CTL019 Ourt of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Novartis, Basel, Switzerland | |
| A Pediatric and Young Adult Trial of Genetically Modified T cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia | NCT02028455 | 1–26 years | Seattle Children’s Hospital, Seattle, WA, USA |
| Pilot Study of T-APCs Following CAR T cell Immunotherapy for CD19 Leukemia | NCT03186118 | 1–26 years | Seattle Children’s Hospital, Seattle, WA, USA |
| CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia | NCT03064269 | 10–60 years | Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, China |
| CART-19 cells for R/R B-ALL (CCFRRBA) | NCT03391739 | 1–60 years | Fujian Medical University, Fuzhou, Fujian, China |
| CART-19 cells for MRD Positive CD19+ ALL (CCFMPCA) | NCT03027739 | 1–60 years | Fujian Medical University, Fuzhou, Fujian, China |
| CD19-specific CAR T cells with a fully human binding domain for CD19+ Leukemia or lymphoma | NCT03684889 | 1–28 years | Seattle Children’s Hospital, Seattle, WA, USA |
| CARPALL: Immunotherapy with CD19 CAR T-cells for CD19+ Haematological Malignancies | NCT02443831 | ≤24 years | University College, London, England |
| CD19/22 CAR T cells (AUTO3) for the treatment of B cell ALL (AMELIA) | NCT03289455 | 1–24 years | Autolus Limited, White City, London, England |
| A feasibility and safety study of CD38 CAR-T cell immunotherapy for relapsed B-cell acute lymphoblastic leukemia after CD19 CAR-T adoptive cellular immunotherapy | NCT03754764 | 12–70 years | Chinese PLA General Hospital, Beijing, China |
| Safety and efficacy evaluation of IM19 CAR-T cells (IM19CAR-T) | NCT03142646 | 4–65 years | Beijing Immunochina Medical Science and Technology Co., Ltd., Beijing, China |
| CD19 CAR-T cells for Patients with Relapse and Refractory CD19+ B-ALL | NCT03671460 | ≥1 year | Tianjin Mycure Medical Technology Co., Ltd., Tianjin, China |
| Anti-CD19 CAR-T Therapy Combien with HSCT to Treat MRD+ B-cell Malignancies | NCT03366324 | ≤70 years | Wuhan Sian Medical Technology Co., Ltd., Wuhan, Hubei, China |
| CD19-CAR-T Cells in Patients with R/R B-ALL | NCT03574168 | 3–70 years | Bioceltech Therapeutics, Ltd., Beijing, China |
| CART-19 for Relapsed/refractory acute Lymphoblastic Leukemia (ALL) | NCT03544021 | 14–75 years | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Shanghai, China |
| A study of C-CAR066 in subjects with r/r B cell Lymphoma who received CD19 CAR-T Therapy | NCT04036019 | 14–70 years | Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China |
| A clinical research of CD20-Targeted CAR-T in B Cell Malignancies | NCT02710149 | 14–75 years | Southwest Hospital China, Chongqing, China |
| A clinical research of CD22-Targeted CAR-T in B Cell Malignancies | NCT02935153 | 14–75 years | Southwest Hospital China, Chongqing, China |
| Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T cell Therapy for Relapsed Refractory B-cell Malignancies | NCT04007978 | 14–70 years | Wuhan Union Hospital, China, Jianghan, Wuhan, China |
| Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | NCT03366350 | ≤70 years | Wuhan Sian Medical Technology Co., Ltd., Wuhan, Hubei, China |
| Humanized CD19 CAR-T Cells with RS Suppression Technology for R/R CD19+ Acute Lymphoblastic Leukemia | NCT03275493 | 6–65 years | Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, China |
| A feasibility and safety study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or refractory Leukemia and Lymphoma | NCT03398967 | 12–70 years | Chinese PLA General Hospital, Beijing, China |
| CD19-CAR Treatment for ALL | NCT03232619 | 6–70 years | Shanghai Bioray Laboratory Inc., Shanghai, China |
| CD19 Chimeric Antigen receptor (CAR)-modified T cell therapy in Treating Patients with B-cell Malignancies | NCT02965092 | ≤70 years | Wuhan Sian Medical Technology Co., Ltd., Whuan, Hubei, China |
| Phase I CD19/CD22 Chimeric Antigen Receptor T cells in Peds Recurrent/Refractory B cell Malignancies | NCT03241940 | 1–30 years | Stanford University, Palo Alto, CA, USA |
| Intravenous Autologou CD19-CAR-T Cells for R/R B-ALL | NCT03937544 | 13–65 years | National University of Malaysia, Bangi, Malaysia |
| Senl_1904A and Senl_1904B Chimeric Antigen Receptor (CAR) T-Cell in the Treatment of r/r Acute B Lymphocytic Leukemia | NCT03840317 | 3–65 years | Henei Senang Biotechnology Inc., Ltd., Shijiazhuang, Hebei, China |
| CART19 Cells Treatment of MRD of B cell Malignancies and then Auto-HSCT | NCT03685786 | 14–75 years | Shenzhen Second People’s Hospital, Shenzhen, China |
| CAR-T Immunotherapy Targeting CD19-ALL | NCT04016129 | 6 months to 75 years | Shenzhen Second People’s Hospital, Shenzhen, China |
| CD19-Directed CAR T cells Therapy in Relapsed/Refractory B cell Malignancy | NCT02537977 | 6–85 years | Shanghai Tongji Hospital, Tongji University School of Medicine |
| CAR-T Therapy Targeting to CD19 for R/R ALL | NCT03919240 | No age posted | The First Affiliated Hospital of Soochow University |
| CD19-targeting, 3rd Generation CAR T Cells for Refractory B cells Malignancy | NCT03068416 | ≤100 years | Uppsala University, Uppsala, Sweden |
| A study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B-ALL | NCT03825718 | 2–70 yrs | Hebei Yanda Ludaopei Hospital, Yanjiao, Hebei, Chin |
| Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T cell Therapy in Treating Patients with B-cell Malignancies | NCT04008251 | 14–70 yrs | Wuhan Sian Medical Technology Co., Ltd., Wuhan, Hubei, China |
| Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukemia Using CAR T-cells to Target CD19 (ALLCAR19) | NCT02935257 | 16– 65 yrs | University College, London, England, UK |
| A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B-ALL | NCT03825731 | 2–70 yrs | Hebei Yanda Ludaopei Hospital, Yanjiao, Hebei, Chin |
| CD19/CD22-targeted Chimeric Antigen Recptor Engineered T cell (CART) in B-cell Acute Lymphblastic Leukemia | NCT03614858 | 6–65 yrs | Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd, Shanghai, China |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies | NCT04033302 | 6 months to 75 yrs | Shenzhen Geno-Immune Medical Institute, Shenzhen, China |
| A Clinical Research of CAR T cells Targeting CD19 Positive Malignant B-ell Derived Leukemia and Lymphoma | NCT02349698 | 4 –75 years | Southwest Hospital China, Chongqing, China |
| MT2017–45: CAR-T Cell Therapy for Heme Malignancies | NCT03642626 | ≤75 years | Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA |
| A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B cell Malignancies | NCT03050190 | ≥6 months | Shenzhen Geno-Immune Medical Institute, Shenzhen, China |
| Production of Clinical-grade Anti-CD19 Chimeric antigen Receptor T cells for Refractory B-cell Malignancies | NCT03624686 | National Taiwan University Hospital, Taipei, Taiwan | |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T cells in Children and Young Adults with Recurrent or Refractory CD19/CD22-expressing B cell Malignancies | NCT03448393 | 3–30 years | National Cancer Institute, Bethesda, MD |
| Autologous T cell expressing a Second Generation CAR for Traemtnet of T-Cell Malignancies Expressing CD5 Antigen (MAGENTA) | NCT03081910 | ≤75 yrs | Baylor College of Medicine, Houston, TX, USA |
| Study of TBI-1501 for Relapsed or Refractory Acute Lymphblastic Leukemia (TBI-1501) | NCT03155191 | ≥16 years | Takara Bio, Inc., Kusatsu, Shiga Prefecture, Japan |
| Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | NCT01853631 | ≤75 years | Baylor College of Medicine, Houston, TX, USA |
| CD19-hsCAR-T for Refractory/Relapsed CD19+ B-ALL Patients | NCT03902197 | 1–75 yrs | Xuanwu Hospital, Beijing, China |
| A Clinical Study Evaluating the Safety and Efficacy of BinD10 Treatment in Childhood R/R ALL and Lymphoma Subjects | NCT03265106 | 1–18 years | ShenZhen BinDeBio Ltd., Shenzhen, China |
| Safety and Efficacy Evaluation of CD19-UCART | NCT03229876 | 6–65 years | Shanghai Bioray Laboratory Inc., Shanghai, China |
| Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy | NCT03910842 | ≤18 years | Timmune Biotech Inc., Hunan, China |